Bone strengthening agent
A bone-strengthening composition using Lactobacillus and Bifidobacterium strains enhances bone health by promoting osteoblast proliferation and inhibiting osteoclast activity, addressing the limitations of existing agents and offering a safe, effective treatment for bone diseases.
Patent Information
- Application Number
- JP2021562636
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-12-02
- Filing Date
- 2020-11-30
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2040-11-30
AI Technical Summary
Existing bone-strengthening agents, such as calcium salts and medications, have low absorption rates and can cause side effects, and there is a need for a safe, effective material that promotes osteoblast proliferation and suppresses osteoclast activity to prevent or treat bone diseases like osteoporosis and arthritis.
A bone-strengthening composition containing bacterial cells and cultures of Lactobacillus, Lactococcus, or Bifidobacterium strains, including specific strains like Lactobacillus delbrueckii subsp. bulgaricus SBT0056 and Bifidobacterium breve SBT10535, which promote osteoblast proliferation and inhibit osteoclast activity.
The composition effectively strengthens bones by promoting osteoblast proliferation and suppressing osteoclast activity, providing a safe and long-term solution for preventing or treating bone diseases without side effects.
Smart Images

Figure 0007596301000001 
Figure 0007596301000002 
Figure 0007596301000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a bone strengthening agent capable of strengthening bones. The present invention has an effect of promoting the proliferation of osteoblasts. In addition, the present invention has an effect of inhibiting bone resorption by osteoclasts. The present invention can provide a material having a bone strengthening effect, which is useful for preventing or treating various bone diseases such as osteoporosis, fracture treatment, rheumatism, and arthritis. Furthermore, the present invention relates to a food or drink for strengthening bones, a nutritional composition for strengthening bones, a feed for strengthening bones, or a medicine for strengthening bones, which contains the material having a bone strengthening effect. This application claims priority based on Japanese Patent Application No. 2019-217705, filed December 2, 2019, the disclosure of which is incorporated herein in its entirety. [Background technology]
[0002] In recent years, various bone-related diseases such as osteoporosis, fractures, and back pain have been increasing worldwide due to aging and other factors. These have become major social issues. This is believed to be due to insufficient calcium intake, decreased calcium absorption ability, and hormonal imbalance after menopause. In order to prevent various bone diseases such as osteoporosis, fractures, and back pain, it is said that it is effective to increase maximum bone mass and bone strength (bone density + bone quality) by promoting bone formation by osteoblasts from a young age and increasing bone mass in the body as much as possible. Note that bone quality refers to the microstructure, metabolic turnover, microfractures, and calcification of bone. In addition, suppressing bone resorption by osteoclasts is also considered as a method of preventing various bone diseases such as osteoporosis, fractures, and back pain. Bones constantly repeat balanced resorption and formation (remodeling). However, due to changes in hormone balance after menopause, bone resorption may exceed bone formation. This causes various bone diseases such as osteoporosis, fractures, and back pain. Therefore, by suppressing bone resorption by osteoclasts and maintaining bone strength at a constant level, it is possible to strengthen bones.
[0003] In view of this situation, calcium salts such as calcium carbonate, calcium phosphate, and calcium lactate, as well as natural calcium agents such as whey calcium, cow bone powder, and eggshell, are added to medicines, foods, beverages, and feeds, and ingested, respectively, for the purpose of strengthening bones. Alternatively, these calcium agents are added to medicines, foods, beverages, and feeds together with substances having a calcium absorption promoting effect, such as casein phosphopeptides or oligosaccharides, and ingested. However, when these calcium salts or natural calcium agents are added to foods and beverages and ingested, it is said that the calcium absorption rate is 50% or less, and more than half of the calcium is not absorbed and is excreted from the body. In addition, the calcium absorbed into the body has different affinity to bones depending on its form or the type of other nutritional components ingested at the same time, so it may not necessarily show an improvement in bone metabolism or bone strengthening effect.
[0004] Other known medicines for osteoporosis treatment or bone strengthening include female hormone preparations, active vitamin D3 preparations, vitamin K2 preparations, bisphosphonate preparations, and calcitonin preparations. Development of new drugs such as anti-RANKL antibodies is also underway. However, the use of these medicines may be accompanied by side effects such as tinnitus, headache, and loss of appetite. Some of these medicines also have a limit on the period of use. Furthermore, these substances cannot currently be added to food and drink due to safety and cost considerations. Therefore, in consideration of the nature of various bone diseases such as osteoporosis, fractures, and back pain, there is a need for the development of a bone strengthening agent that can be taken for a long time without side effects, acts to promote bone formation and / or inhibit bone resorption to increase bone strength, and is expected to have a preventive or therapeutic effect, as well as food, drink, and feed containing such a bone strengthening agent.
[0005] It is known that a culture of Propionibacterium freudenreichii promotes differentiation of an established osteoblast cell line and inhibits differentiation of cultured osteoclasts (Patent Document 1). However, it has not been known that bacterial components of lactic acid bacteria and / or bifidobacteria or cultures thereof promote the proliferation of osteoblasts and inhibit bone resorption by osteoclasts. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] Patent No. 4750991 Summary of the Invention [Problem to be solved by the invention]
[0007] The object of the present invention is to provide a material having a bone strengthening effect capable of strengthening bones. This material is highly safe and has an effect of promoting the proliferation of osteoblasts. In addition, this material has an effect of inhibiting bone resorption by osteoclasts. In addition, this material is useful for preventing or treating various bone diseases such as osteoporosis, bone fractures, rheumatism, and arthritis. In addition, the object of the present invention is to provide a bone strengthening agent, a food or drink for bone strengthening, a nutritional composition for bone strengthening, a feed for bone strengthening, or a medicine for bone strengthening, which contains a material having a bone strengthening effect that is useful for preventing or treating various bone diseases such as osteoporosis, bone fractures, rheumatism, and arthritis. These have an effect of promoting the proliferation of osteoblasts. These also have an effect of inhibiting bone resorption by osteoclasts, and can strengthen bones. [Means for solving the problem]
[0008] As a result of intensive research conducted by the present inventors to solve the above problems, it was found that some lactic acid bacteria or bifidobacteria have a bone strengthening effect. (1) A composition for strengthening bone, comprising as an active ingredient a bacterial cell and / or a culture of a bacterium belonging to the genus Lactobacillus, Lactococcus, or Bifidobacterium. (2) A composition for strengthening bone according to (1), characterized in that the bacteria belonging to the genus Lactobacillus, Lactococcus, or Bifidobacterium are one or more selected from the group consisting of Lactobacillus delbrueckii, Lactobacillus helveticus, Lactobacillus gasseri, Lactobacillus reuteri, Lactococcus lactis, Bifidobacterium breve, and Bifidobacterium adolescentis. (3) A bone-strengthening composition according to (2), characterized in that the bacteria belonging to Lactobacillus delbrueckii or Lactococcus lactis are bacteria belonging to Lactobacillus delbrueckii subsp. bulgaricus or Lactococcus lactis subsp. lactis. (4) The bacterium belonging to the genus Lactobacillus, Lactococcus, or Bifidobacterium is selected from the group consisting of Lactobacillus delbrueckii subsp. bulgaricus SBT2115 strain (NITE P-03074), SBT0056 strain (NITE P-03073), Lactobacillus helveticus SBT2161 strain (NITE BP-01707), SBT11380 strain (NITE BP-02644), and SBT2192A strain (NITE P-03077), Lactobacillus gasseri SBT2054 strain (NITE P-03076), and SBT1848 strain (NITE P-03078). P-03075), Lactobacillus reuteri SBT10010 strain (NITE BP-02997), Lactococcus lactis subsp. lactis SBT0625 strain (NITE ABP-03078), SBT2483 strain (NITE P-03081), SBT1223 strain (NITE P-03003), SBT1554 strain (NITE P-03079), SBT2397 strain (NITE P-03080), Bifidobacterium breve SBT10535 strain (NITE P-03071), SBT10561 strain (NITE The bone strengthening composition according to any one of (1) to (3), characterized in that the composition is one or more selected from the group consisting of Bifidobacterium adolescentis SBT10549 strain (NITE P-03070), Bifidobacterium adolescentis SBT10549 strain (NITE P-03072), and Bifidobacterium adolescentis SBT10549 strain (NITE P-03070). (5) A bone-strengthening food or drink, a bone-strengthening nutritional composition, a bone-strengthening feed, or a bone-strengthening medicine, comprising the bone-strengthening composition according to any one of (1) to (4). (6) A novel lactic acid bacterium, Lactobacillus delbrueckii subsp. bulgaricus SBT0056. (7) A novel lactic acid bacterium, Lactobacillus helveticus SBT2192A strain. (8) A novel lactic acid bacterium, Lactococcus lactis subsp. lactis SBT0625 strain. (9) A novel lactic acid bacterium, Lactococcus lactis subsp. lactis SBT2483 strain. (10) A novel lactic acid bacterium, Lactococcus lactis subsp. lactis SBT1223 strain. (11) A novel lactic acid bacterium, Lactococcus lactis subsp. lactis SBT1554 strain. (12) A novel lactic acid bacterium, Lactococcus lactis subsp. lactis SBT2397 strain. (13) A novel bifidobacterium, Bifidobacterium breve SBT10535 strain. (14) A novel bifidobacterium, Bifidobacterium breve SBT10561 strain. (15) A novel bifidobacterium, Bifidobacterium adolescentis SBT10549 strain. (16) Use of bacteria belonging to the genus Lactobacillus, Lactococcus, or Bifidobacterium and / or a culture thereof for the production of a bone strengthening composition. (17) Bacterial cells and / or cultures thereof belonging to the genus Lactobacillus, Lactococcus, or Bifidobacterium for use in bone strengthening. (18) A method for strengthening bone, comprising ingesting or administering to a subject in need thereof an effective amount of a bacterium belonging to the genus Lactobacillus, Lactococcus, or Bifidobacterium and / or a culture thereof. Effect of the Invention
[0009] The bone strengthening composition of the present invention is highly safe and can promote the proliferation of osteoblasts. In addition, the bone strengthening composition of the present invention has a remarkable bone strengthening effect through the effect of suppressing both the differentiation of osteoclasts and bone resorption by the cells. The bone strengthening composition is useful for the prevention or treatment of various bone diseases such as osteoporosis, bone fracture, rheumatism, and arthritis. The present invention can also promote the proliferation of osteoblasts. The present invention also has an effect of suppressing both the differentiation of osteoclasts and bone resorption by the cells, and can strengthen bones. Therefore, the present invention provides a bone strengthening food and drink, a bone strengthening nutritional composition, a bone strengthening feed, or a bone strengthening pharmaceutical product containing the bone strengthening composition, which is useful for the prevention or treatment of various bone diseases such as osteoporosis, bone fracture, rheumatism, and arthritis. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] As the lactic acid bacteria that can be used in the present invention, any lactic acid bacteria that belong to the genus Lactobacillus or Lactococcus and have a bone strengthening effect can be used. As the bifidobacteria, any bifidobacteria that belong to the genus Bifidobacterium and have a bone strengthening effect can be used. As the lactic acid bacteria that belong to the genus Lactobacillus, lactic acid bacteria that belong to Lactobacillus delbrueckii, Lactobacillus helveticus, Lactobacillus gasseri, Lactobacillus reuteri, etc. can be exemplified. As the lactic acid bacteria that belong to the genus Lactococcus, lactic acid bacteria that belong to Lactococcus lactis, etc. can be exemplified. Examples of bifidobacteria belonging to the genus Bifidobacterium include bifidobacterium breve and bifidobacterium adolescentis. Examples of lactic acid bacteria belonging to Lactobacillus delbrueckii include Lactobacillus delbrueckii subsp. bulgaricus. Examples of lactic acid bacteria belonging to Lactococcus lactis include Lactococcus lactis subsp. lactis. Any of the lactic acid bacteria or bifidobacteria are not limited to those exemplified above. Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus helveticus, Lactobacillus gasseri, Lactobacillus reuteri, Lactococcus lactis subsp. lactis, Bifidobacterium breve, and Bifidobacterium adolescentis that can be used in the present invention can be classified by common classification methods such as 16S ribosomal RNA gene sequence analysis. In the present invention, in particular, Lactobacillus delbrueckii subsp. bulgaricus SBT0056 strain (NITE P-03073), SBT2115 strain (NITE P-03074), Lactobacillus helveticus SBT2161 strain (NITE BP-01707), SBT11380 strain (NITE BP-02644), 2192A strain (NITE P-03077), Lactobacillus gasseri SBT2054 strain (NITE P-03076), SBT1848 strain (NITE P-03075), Lactobacillus reuteri reuteri SBT10010 strain (NITE BP-02997), Lactococcus lactis subsp. lactis SBT0625 strain (NITE ABP-03078), SBT2483 strain (NITE P-03081), SBT1223 strain (NITE P-03003), SBT1554 strain (NITE P-03079), SBT2397 strain (NITE P-03080), Bifidobacterium breve SBT10535 strain (NITE P-03071), SBT10561 strain (NITE ABP-03072), or Bifidobacterium adolescentis It is preferable to use, but not limited to, S. adolescentis SBT10549 strain (NITE P-03070). The bone strengthening composition of the present invention may contain one or more of the bacteria belonging to the genus Lactobacillus, Lactococcus, or Bifidobacterium, and their cultures. The active ingredient of the present invention may be composed of each of the bacteria belonging to the genus Lactobacillus, Lactococcus, or Bifidobacterium. The active ingredient of the present invention may be composed of each of the bacteria belonging to the genus Lactobacillus, Lactococcus, or Bifidobacterium.
[0011] (Cultivation method of lactic acid bacteria or bifidobacteria) The lactic acid bacteria or bifidobacteria used in the present invention can be cultured according to a conventional method for culturing lactic acid bacteria or bifidobacteria. Various culture media can be used as the culture medium, such as a milk medium or a medium containing milk components, a milk medium or a semi-synthetic medium not containing milk components. Examples of such media include reduced skim milk medium. The cells separated from the obtained culture by a collection means such as centrifugation can be used as they are as the active ingredient of the present invention. Cells that have been concentrated, dried, or freeze-dried can also be used. The cells may be killed by heating and drying. Not only purely isolated cells, but also cultures, suspensions, or other cell-containing materials, as well as cytoplasm or cell wall fractions obtained by treating cells with enzymes or physical means can be used. Examples of the form of the culture include, but are not limited to, cultures using synthetic media such as MRS medium (DIFCO), M17 medium (DIFCO), 1% glucose-containing GAM medium (Nissui Pharmaceutical), and reduced skim milk medium, which are generally used for culturing lactic acid bacteria, as well as dairy products such as cheese, fermented milk, and lactic acid bacteria drinks. In addition, culture supernatants prepared by removing milk protein precipitates and bacterial components from the obtained cultures using methods such as centrifugation and filtration can also be used. Such culture supernatants have a low solid content, so they can be applied to a wide range of foods and beverages. For example, a culture supernatant can be prepared by centrifuging a reduced skim milk culture at 5,000 rpm for 10 minutes.
[0012] (New lactic acid bacteria strain or new bifidobacteria strain) The present invention relates to novel lactic acid bacteria strains or novel bifidobacterial strains. These novel lactic acid bacteria strains or novel bifidobacterial strains include Lactobacillus delbrueckii subsp. bulgaricus strain SBT0056 (NITE P-03073), Lactobacillus helveticus strain SBT2192A (NITE P-03077), Lactococcus lactis subsp. lactis strain SBT0625 (NITE ABP-03078), Lactococcus lactis subsp. lactis strain SBT2483 (NITE P-03081), Lactococcus lactis subsp. lactis strain SBT1223 (NITE P-03003), Lactococcus lactis subsp. lactis strain SBT1554 (NITE P-03004), and the like. lactis SBT2397 strain (NITE P-03080), Bifidobacterium breve SBT10535 strain (NITE P-03071), Bifidobacterium breve SBT10561 strain (NITE ABP-03072), and Bifidobacterium adolescentis SBT10549 strain (NITE P-03070). Hereinafter, these lactic acid bacteria or bifidobacterial strains may be referred to as "lactic acid bacteria or bifidobacteria of the present invention," "lactic acid bacteria or bifidobacterial strains of the present invention," or simply as SBT0056 strain, SBT2192A strain, SBT0625 strain, SBT2483 strain, SBT1223 strain, SBT1554 strain, SBT2397 strain, SBT10535 strain, SBT10561 strain, or SBT10549 strain. Of these lactic acid bacteria strains, the SBT1223 strain was deposited on July 8, 2019 at the National Institute of Technology and Evaluation, Patent Microorganisms Deposit Center (Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, 292-0818) under the accession number NITE P-03003. The other strains were deposited on November 25, 2019 at the Patent Microorganism Deposit Center of the National Institute of Technology and Evaluation (Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, 292-0818) under the accession numbers NITE P-03073 for SBT0056, NITE P-03077 for SBT2192A, NITE P-03078 for SBT0625, NITE ABP-03078 for SBT2483, NITE P-03081 for SBT1554, NITE P-03079 for SBT2397, NITE P-03080 for SBT10535, NITE P-03071 for SBT10561, and NITE ABP-03072 for SBT10549. The lactic acid bacteria or bifidobacteria of the present invention are not limited to the above deposited lactic acid bacteria or bifidobacteria strains, and may be substantially equivalent to these deposited lactic acid bacteria or bifidobacteria strains. The substantially equivalent lactic acid bacteria or bifidobacteria strains refer to lactic acid bacteria or bifidobacteria strains belonging to Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus helveticus, Lactobacillus gasseri, Lactobacillus reuteri, Lactococcus lactis subsp. lactis, Bifidobacterium breve, or Bifidobacterium adolescentis, which have a high bone strengthening effect equivalent to that of the deposited lactic acid bacteria or bifidobacteria strains. The term "lactic acid bacteria strain or bifidobacterial strain having a bone-strengthening effect as high as that of the deposited lactic acid bacteria strain or bifidobacterial strain" refers to, for example, a lactic acid bacteria strain or bifidobacterial strain whose osteoblast proliferation-promoting effect measured by the following procedures 1) to 3) or whose bone resorption-inhibiting effect measured by the following procedures 4) to 6) is not significantly different from the osteoblast proliferation-promoting effect or bone resorption-inhibiting effect of each deposited lactic acid bacteria strain or bifidobacterial strain. (Method for evaluating osteoblast proliferation promoting effect) 1) An osteoblast cell line (MC3T3-E1) is seeded onto a 96-well flat cell culture plate at 4,000 cells / well, and cultured in α-MEM medium containing 10% (v / v) fetal bovine serum for 24 hours. 2) After removing the entire medium, replace it with α-MEM medium that does not contain fetal bovine serum, add various lactic acid bacteria or bifidobacterial bodies to the medium to a final concentration of 5 μg / ml, and culture for a further 24 hours. 3) Bromodeoxyuridine (BrdU) included in the Cell Proliferation kit (GE Healthcare) is added and incubated for 2 hours. Then, it is reacted with peroxidase-labeled anti-BrdU antibody. Then, the substrate 3,3',5,5'-tetramethylbenzidine is added and the absorbance at 450 nm is measured. (Method for evaluating bone resorption inhibitory effect) 4) The tibia and femur of 5-day-old rabbits were excised and the soft tissue was removed.Then, the whole bone marrow cells including osteoclasts mechanically chopped in α-MEM medium containing 5% (v / v) FBS were seeded on the wells of crystalline calcium phosphate plates (manufactured by Corning) at 500,000 cells / well and cultured. 5) After 2 hours of culture, the medium is replaced with a new one, and various lactic acid bacteria or bifidobacterial bacteria are then added to the medium to a final concentration of 100 μg / ml, followed by culturing for 72 hours. 6) Remove all the medium and add 5% sodium hypochlorite solution to remove the cells. Then, take a picture of the bone resorption pits formed on the wells of the calcium phosphate plate under a stereomicroscope. The effect of inhibiting bone resorption by osteoclasts is examined by measuring the area through image analysis (Koji Seno et al., Animal Culture Cell Manual by Research Theme, pp.199-200, 1993). In the present invention, "bone strengthening" means increasing at least one of bone mass, bone density, and bone quality by promoting proliferation of osteoblasts and / or inhibiting differentiation of osteoclasts or inhibiting bone resorption by osteoclasts. "Bone strengthening" may be an in vitro effect or an in vivo effect. In the case of an in vivo effect, "bone strengthening" may mean promoting proliferation of osteoblasts and / or inhibiting bone resorption. When the lactic acid bacteria or bifidobacteria of the present invention are evaluated for their osteoblast proliferation-promoting effect according to the above steps 1) to 3), the measured cell proliferation-promoting effect is preferably at least 1.5 times, more preferably at least 2 times, greater than the osteoblast proliferation-promoting effect in a control to which no lactic acid bacteria or bifidobacterial strain has been added. Note that the "measured cell proliferation-promoting effect" refers to the magnitude of the absorbance value measured after the above steps 1) to 3). Furthermore, when the lactic acid bacteria or bifidobacteria of the present invention are evaluated for bone resorption inhibitory effect by the above-mentioned steps 4) to 6), the measured bone resorption inhibitory effect is preferably at least 2 times, more preferably at least 4 times, and even more preferably at least 6 times, greater than the bone resorption inhibitory effect in a control to which no lactic acid bacteria or bifidobacteria strain is added. The "measured bone resorption inhibitory effect" refers to the area of the pits measured after the above-mentioned steps 4) to 6). The smaller the area of the pits, the greater the bone resorption inhibitory effect. For example, in Test Example 2 described below, when Lactococcus lactis subsp. lactis SBT0625 strain suspended in PBS was added, the area of the pits formed on the wells of the calcium phosphate plate was less than one-tenth of that of the control (PBS only). Needless to say, the evaluation methods are not limited to those described above, and the osteoblast proliferation-promoting effect or bone resorption-inhibiting effect can be evaluated by adopting any method for evaluating the osteoblast proliferation-promoting effect or the bone resorption-inhibiting effect that is known to those skilled in the art. Furthermore, the substantially equivalent lactic acid bacteria or bifidobacterial strain has a base sequence of its 16S rRNA gene that is 98% or more, preferably 99% or more, more preferably 100% homologous to the base sequence of the 16S rRNA gene of the deposited lactic acid bacteria or bifidobacterial strain, and preferably has the same bacteriological properties as the deposited lactic acid bacteria or bifidobacterial strain. Furthermore, the lactic acid bacteria or bifidobacterial strain of the present invention may be a lactic acid bacteria or bifidobacterial strain bred from the deposited lactic acid bacteria or bifidobacterial strain or a substantially equivalent lactic acid bacteria or bifidobacterial strain by mutation treatment, genetic recombination, selection of natural mutants, or the like, so long as the effects of the present invention are not impaired.
[0013] (Amount of active ingredient taken) The intake amount of the lactic acid bacteria or bifidobacteria of the present invention is not particularly limited as long as it is an effective amount that exhibits a bone strengthening effect through the action of promoting the proliferation of osteoblasts or the action of inhibiting the differentiation of osteoclasts and bone resorption by said cells. Therefore, the intake amount may be appropriately adjusted according to the ease of production and the preferred daily intake amount. The subject of the present invention is not particularly limited, and the subject of the present invention may be administered to humans, but may also be animals other than humans (e.g., dogs, cats, horses, cows, rabbits, etc.). When the subject of the present invention is a human, it may be administered to minors under 20 years old, adults, men and women, or elderly people over 65 years old. The intake amount of the lactic acid bacteria or bifidobacteria of the present invention is determined individually taking into consideration the symptoms, age, and sex of the subject, but for normal adults, the blending amount may be adjusted so that 10 to 200 g of the culture of lactic acid bacteria or bifidobacteria or 0.1 to 5,000 mg of the bacteria can be ingested. The lactic acid bacteria or bifidobacteria of the present invention may be orally ingested as is, but when the lactic acid bacteria or bifidobacteria are added to foods and beverages, nutritional compositions, feed, oral medicines, etc., the amount of the lactic acid bacteria or bifidobacteria added may be adjusted to the above-mentioned intake amount. By ingesting the lactic acid bacteria or bifidobacteria in this manner, the desired effects can be achieved. The subjects to be treated may be patients suffering from various bone diseases such as osteoporosis, bone fractures, rheumatism, and arthritis, or may be subjects at high risk of developing such diseases, or may be healthy subjects who are not yet affected but may be at risk of developing such diseases in the future.
[0014] (Method of using the lactic acid bacteria or bifidobacteria of the present invention in foods, beverages, and pharmaceuticals) The lactic acid bacteria or bifidobacteria of the present invention may be used as a bone strengthening composition, either alone or in any combination. In addition, they may be formulated into powders, granules, tablets, capsules, drinks, etc., as necessary, according to a conventional method, within a range that does not lose the bone strengthening effect via the effect of promoting the proliferation of osteoblasts or the effect of inhibiting the differentiation of osteoclasts and bone resorption by said cells. They may also be incorporated into foods and drinks, such as nutritional supplements, powdered milk, milk drinks, lactic acid bacteria drinks, fermented milk, soft drinks, cheese, margarine, cream, pudding, jelly, or wafers, nutritional compositions, feeds, and medicines, either as is or after formulation. The lactic acid bacteria or bifidobacterium cells or cultures of the present invention can be used together with other raw materials such as stabilizers, sugars, lipids, flavors, vitamins, minerals, flavonoids, polyphenols, etc. that are commonly contained in foods, beverages, feeds, and medicines.
[0015] In the formulation, commonly used diluents or excipients such as fillers, extenders, binders, disintegrants, surfactants, and lubricants can be used. As the excipients, for example, sucrose, lactose, starch, crystalline cellulose, mannitol, light anhydrous silicic acid, magnesium aluminate, synthetic aluminum silicate, magnesium aluminometasilicate, calcium carbonate, sodium hydrogen carbonate, calcium hydrogen phosphate, and calcium carboxymethylcellulose can be added alone or in combination. Furthermore, the food and drink of the present invention can also be used as a functional food, a food for specified health uses, a food with nutrient function claims, or a cosmetic food.
[0016] The present invention will be described in detail below with reference to Examples and Test Examples, but the present invention is not limited thereto. In this specification, % indicates % by mass unless otherwise specified. EXAMPLES
[0017] Example 1 Lactobacillus delbrueckii subsp. bulgaricus SBT0056, SBT2115, Lactobacillus helveticus SBT2161, SBT11380, 2192A, Lactobacillus gasseri SBT2054, SBT1848, and Lactobacillus reuteri SBT10010 were activated by culturing each strain at 37°C for 16 hours in sterilized MRS broth (DIFCO) for more than three generations. The cultures were inoculated into the same medium at 3% (v / v) and cultured at 37°C for 16 hours. Then, each bacterial body was separated by centrifugation. The cells were washed twice with sterile saline and once with ultrapure water, and then freeze-dried. By the above procedure, the cells of Lactobacillus delbrueckii subsp. bulgaricus SBT0056 strain, SBT2115 strain, Lactobacillus helveticus SBT2161 strain, SBT11380 strain, 2192A strain, Lactobacillus gasseri SBT2054 strain, SBT1848 strain, and Lactobacillus reuteri SBT10010 strain were obtained (Example Product 1).The thus obtained Lactobacillus delbrueckii subsp. bulgaricus SBT0056 strain, SBT2115 strain, Lactobacillus helveticus SBT2161 strain, SBT11380 strain, 2192A strain, or Lactobacillus gasseri SBT2054 strain, SBT1848 strain, or Lactobacillus reuteri SBT10010 strain can be used as is as the lactic acid bacteria having a bone-strengthening effect of the present invention.
[0018] Example 2 Lactococcus lactis subsp. lactis strains SBT0625, SBT2483, SBT1223, SBT1554, and SBT2397 were activated by culturing each strain at 30°C for 16 hours for more than three generations in sterilized M17 medium (DIFCO) containing 0.5% lactose. The cultures were inoculated into the same medium at 3% (v / v) and cultured at 30°C for 16 hours. The cells were then separated by centrifugation. The cells were washed twice with sterile saline and once with ultrapure water, and then lyophilized. By the above-mentioned operation, the bacterial cells of Lactococcus lactis subsp. lactis SBT0625, SBT2483, SBT1223, SBT1554, and SBT2397 strains were obtained (Example Product 2). The bacterial cells of Lactococcus lactis subsp. lactis SBT0625, SBT2483, SBT1223, SBT1554, and SBT2397 strains thus obtained can be used as they are as the lactic acid bacteria having bone strengthening effect of the present invention.
[0019] Example 3 Bifidobacterium breve SBT10535, SBT10561, or Bifidobacterium adolescentis SBT10549 was activated by culturing each strain at 30°C for 16 hours for more than three generations in sterilized 1% glucose-containing GAM medium (Nissui Pharmaceutical Co., Ltd.). The cultures were inoculated into the same medium at 3% (v / v) and cultured at 37°C for 16 hours. The cells were then separated by centrifugation. The cells were washed twice with sterile saline and once with ultrapure water, and then lyophilized. By the above-mentioned operation, the bacterial cells of Bifidobacterium breve SBT10535 strain, SBT10561 strain, and Bifidobacterium adolescentis SBT10549 strain were obtained (Example Product 3). The bacterial cells of Bifidobacterium breve SBT10535 strain, SBT10561 strain, and Bifidobacterium adolescentis SBT10549 strain obtained in this manner can be used as they are as the bifidobacteria having bone strengthening effect of the present invention.
[0020] Comparative Example 1 Leuconostoc mesenteroides subsp. mesenteroides No.1 strain owned by Megmilk Snow Brand Co., Ltd. was activated by culturing it in sterilized MRS broth (DIFCO) at 37°C for 16 hours for more than three generations. This was inoculated into the same medium at 3% (v / v) and cultured at 37°C for 16 hours. Then, each bacterial body was separated by centrifugation. The bacterial body was washed twice with sterile saline and once with ultrapure water, and then lyophilized. By the above operation, the bacterial body of Leuconostoc mesenteroides subsp. mesenteroides No.1 strain was obtained (Comparative Example Product 1).
[0021] Comparative Example 2 Streptococcus mitis No.1 strain owned by Megmilk Snow Brand Co., Ltd. was activated by culturing it in sterilized M17 medium (DIFCO) containing 0.5% lactose at 30°C for 16 hours for more than three generations. This was inoculated into the same medium at 3% (v / v) and cultured at 37°C for 16 hours. Then, each bacterial body was separated by centrifugation. The bacterial bodies were washed twice with sterile saline and once with ultrapure water, and then lyophilized. By the above operation, the bacterial bodies of Streptococcus mitis No.1 strain were obtained (Comparative Example 2).
[0022] (Test Example 1) The osteoblast proliferation promoting effects of the following bacteria were investigated: Lactobacillus delbrueckii subsp. bulgaricus SBT0056 strain, SBT2115 strain, Lactobacillus helveticus SBT2161 strain, SBT11380 strain, 2192A strain, Lactobacillus gasseri SBT2054 strain, SBT1848 strain (Example Product 1); Lactococcus lactis subsp. lactis SBT0625 strain (Example Product 2); and Bifidobacterium breve SBT10535 strain, SBT10561 strain (Example Product 3). For comparison, the effect of the bacteria of Leuconostoc mesenteroides subsp. mesenteroides No. 1 strain (Comparative Example 1) and Streptococcus mitis No. 1 strain (Comparative Example 2) on promoting osteoblast proliferation was examined. The established osteoblast cell line (MC3T3-E1) was seeded at 4,000 cells / well on a 96-well flat cell culture plate and cultured for 24 hours in α-MEM medium containing 10% (v / v) fetal bovine serum. After removing the entire medium, it was replaced with α-MEM medium without fetal bovine serum. Then, the bacteria of the present invention were added to the medium to a final concentration of 5 μg / ml and cultured for another 24 hours. Bromodeoxyuridine (BrdU) included in the Cell Proliferation kit (GE Healthcare) was added and cultured for 2 hours. Then, the cells were reacted with peroxidase-labeled anti-BrdU antibody, and the substrate 3,3',5,5'-tetramethylbenzidine was added. The absorbance at 450 nm was then measured. By carrying out the above procedure, the amount of BrdU taken up into the cells was measured, and the osteoblast proliferation promoting effect was determined. The results are shown in Table 1.
[0023] [Table 1]
[0024] As a result, when Lactobacillus delbrueckii subsp. bulgaricus SBT0056 strain, SBT2115 strain, Lactobacillus helveticus SBT2161 strain, SBT11380 strain, 2192A strain, Lactobacillus gasseri SBT2054 strain, SBT1848 strain, Lactococcus lactis subsp. lactis SBT0625 strain, Bifidobacterium breve SBT10535 strain, SBT10561 strain were added, the proliferation of osteoblasts was significantly promoted in all cases compared to the control (PBS). From these results, it was found that the bacterial cells of Lactobacillus delbrueckii subsp. bulgaricus SBT0056 strain and SBT2115 strain, Lactobacillus helveticus SBT2161 strain, SBT11380 strain, and 2192A strain of the present invention, Lactobacillus gasseri SBT2054 strain and SBT1848 strain, Lactococcus lactis subsp. lactis SBT0625 strain of Example Product 2, and Bifidobacterium breve SBT10535 strain and SBT10561 strain of Example Product 3 have an osteoblast proliferation promoting effect. On the other hand, the bacterial cells of Leuconostoc mesenteroides subsp. mesenteroides No. 1 strain (Comparative Example Product 1) and Streptococcus mitis No. 1 strain (Comparative Example Product 2) did not exhibit any proliferation-promoting effect on osteoblasts.
[0025] (Test Example 2) The bone resorption inhibitory effects of the following bacteria were investigated: Lactobacillus reuteri SBT10010 strain (Example Product 1); Lactococcus lactis subsp. lactis SBT0625 strain, SBT2483 strain, SBT1223 strain, SBT1554 strain, SBT2397 strain (Example Product 2); and Bifidobacterium adolescentis SBT10549 strain (Example Product 3). For comparison, the bone resorption inhibitory effect of the bacteria of Leuconostoc mesenteroides subsp. mesenteroides No. 1 strain (Comparative Example 1) and Streptococcus mitis No. 1 strain (Comparative Example 2) was examined. The tibia and femur of a 5-day-old rabbit were excised and the soft tissue was removed. Then, whole bone marrow cells including osteoclasts mechanically chopped in α-MEM medium containing 5% (v / v) FBS were seeded on the wells of a crystalline calcium phosphate plate (manufactured by Corning) at 500,000 cells / well and cultured. After 2 hours of culture, the medium was replaced with a new one, and the bacteria of the present invention were added to the medium at a final concentration of 100 μg / ml and cultured for 72 hours. After removing the cells by adding 5% sodium hypochlorite solution, the bone resorption pits formed on the wells of the calcium phosphate plate were photographed under a stereomicroscope. The effect of inhibiting bone resorption by osteoclasts was investigated by measuring the area through image analysis (Koji Seno et al., Animal Culture Cell Manual by Research Theme, pp.199-200, 1993). The results are shown in Table 2.
[0026] [Table 2]
[0027] As a result, when the cells of Lactobacillus reuteri SBT10010, Lactococcus lactis subsp. lactis SBT0625, SBT2483, SBT1223, SBT1554, SBT2397, and Bifidobacterium adolescentis SBT10549 were added, the area of the pits was significantly reduced compared to the control (PBS). From these results, it was confirmed that the Lactobacillus reuteri of the present invention It was found that the bacteria Lactobacillus reuteri SBT10010, Lactococcus lactis subsp. lactis SBT0625, SBT2483, SBT1223, SBT1554, SBT2397, and Bifidobacterium adolescentis SBT10549 have an inhibitory effect on bone resorption by osteoclasts. On the other hand, the bacteria Leuconostoc mesenteroides subsp. mesenteroides No. 1 (Comparative Example 1) and Streptococcus mitis No. 1 (Comparative Example 2) did not show any inhibitory effect on bone resorption by osteoclasts.
[0028] Example 4 (Preparation of capsules for bone strengthening) The raw materials were mixed according to the composition shown in Table 3, granulated by a conventional method, and filled into capsules to produce the bone-strengthening capsule preparation of the present invention.
[0029] [Table 3]
[0030] Example 5 (Preparation of bone strengthening tablets) The raw materials were mixed according to the composition shown in Table 4, and then molded into 1 g tablets by a conventional method to produce the bone-strengthening tablets of the present invention.
[0031] [Table 4]
[0032] Example 6 (Preparation of liquid nutritional composition for bone strengthening) 25 g of SBT10561 strain cells (Example Product 3) were dissolved in 4,975 g of deionized water and heated to 40°C. The solution was then stirred and mixed at 6,000 rpm for 10 minutes using a TK homogenizer (TK ROBO MICS; manufactured by Tokushu Kika Kogyo Co., Ltd.) to obtain a 25 g / 5 kg SBT10561 strain cell solution. 5.0 kg of this SBT10561 strain solution was mixed with 5.0 kg of casein, 5.0 kg of soy protein, 1.0 kg of fish oil, 3.0 kg of perilla oil, 17.0 kg of dextrin, 6.0 kg of mineral mixture, 1.95 kg of vitamin mixture, 2.0 kg of emulsifier, 4.0 kg of stabilizer, and 0.05 kg of flavoring, filled into a 200 ml retort pouch, and sterilized at 121°C for 20 minutes in a retort sterilizer (first class pressure vessel, TYPE: RCS-4CRTGN, manufactured by Hisaka Works, Ltd.) to produce 50 kg of the liquid nutritional composition for bone strengthening of the present invention. Note that 200 g of the liquid nutritional composition for bone strengthening of the present invention contained 100 mg of the SBT10561 strain cells.
[0033] Example 7 (Preparation of Bone Strengthening Drink) 0.5g of the SBT2161 strain of Example 1 was dissolved in 699.5g of deionized water, heated to 40°C, and then stirred and mixed for 20 minutes at 9,500 rpm with an Ultra Disperser (ULTRA-TURRAX T-25; manufactured by IKA Japan Co., Ltd.). 100g of maltitol, 2g of acidulant, 20g of reduced water, 2g of flavoring, and 176g of deionized water were added, and the mixture was filled into a 100ml glass bottle, sterilized at 95°C for 15 seconds, and then sealed to prepare 10 bottles (100ml) of the bone strengthening beverage of the present invention. Note that 100g of the bone strengthening beverage of the present invention contained 50mg of the SBT2161 strain of bacteria.
[0034] Example 8 (Preparation of bone strengthening food for dogs) 2g of the SBT10549 strain of Example 3 was dissolved in 3,998g of deionized water, heated to 40°C, and then stirred and mixed for 20 minutes at 3,600 rpm in a TK homomixer (MARK II 160 type; manufactured by Tokushu Kika Kogyo Co., Ltd.) to obtain a 2g / 4kg SBT10549 strain cell solution. 2kg of this SBT10549 strain cell solution was mixed with 1kg soybean meal, 1kg skim milk powder, 0.4kg soybean oil, 0.2kg corn oil, 2.3kg palm oil, 1kg corn starch, 0.9kg wheat flour, 0.2kg bran, 0.5kg vitamin mixture, 0.3kg cellulose, and 0.2kg mineral mixture, and sterilized at 120°C for 4 minutes to produce 10kg of the bone strengthening feed of the present invention. The bone-strengthening feed of the present invention contained 10 mg of the SBT10549 strain cells per 100 g.
[0035] Example 9 (Preparation of bone strengthening milk powder) 2g of the SBT0056 strain of Example 1, 9.998kg of skim milk powder, and 90kg of deionized water were mixed and heated to 40°C, and then stirred and mixed for 10 minutes at 6,000 rpm in a TK homomixer (TK ROBO MICS; manufactured by Tokushu Kika Kogyo Co., Ltd.). This solution was spray-dried to produce 10kg of bone strengthening milk powder of the present invention. The 10g of bone strengthening milk powder of the present invention contained 2mg of the SBT0056 strain.
[0036] Example 10 (Preparation of bone strengthening milk drink) 1 g of the SBT1223 strain cells of Example Product 2 and 9.999 kg of milk were mixed and heated to 40°C, and then stirred and mixed for 10 minutes at 6,000 rpm in a TK homogenizer (TK ROBO MICS; manufactured by Tokushu Kika Kogyo Co., Ltd.). The mixture was heat-sterilized at 130°C for 2 seconds, and then cooled to 10°C or lower to produce 10 kg of the bone-strengthening milk drink of the present invention. Note that 200 g of the bone-strengthening milk drink of the present invention contained 20 mg of the SBT1223 strain cells.
[0037] Example 11 (Preparation of fermented milk for bone strengthening) 0.1 g of the SBT0625 strain of Example Product 2, 1700 g of skim milk powder, 300 g of glucose, and 7699.9 g of deionized water were mixed and sterilized by heating at 95 ° C for 2 hours. This was cooled to 37 ° C, 300 g of lactic acid bacteria starter (Streptococcus thermophilus) was inoculated, stirred and mixed, and fermented to pH 4.0 in an incubator maintained at 37 ° C. After reaching pH 4.0, it was cooled to 10 ° C or less to produce 10 kg of fermented milk for bone strengthening of the present invention. Note that 200 g of the fermented milk for bone strengthening of the present invention contained 2 mg of the SBT0625 strain.
[0038] Example 12 (Preparation of lactic acid bacteria drink for bone strengthening) 1700g of skim milk powder, 300g of glucose, and 7700g of deionized water were mixed and sterilized by heating at 95°C for 2 hours. This was cooled to 37°C, 300g of lactic acid bacteria starter (Lb.casei) was inoculated, stirred and mixed, and fermented to pH 4.0 in an incubator kept at 37°C. After reaching pH 4.0, it was cooled to 10°C or less while stirring to obtain a fermentation base. In addition, 4g of the SBT10010 strain of Example Product 1, 1800g of white sugar, 20g of acidulant, 10g of flavoring, and 8166g of deionized water were mixed, sterilized at 90°C for 10 minutes, and then cooled to 10°C or less to obtain a sugar solution. 2000 g of the fermentation base and 8000 g of the sugar solution were mixed, smoothed with a homogenizer, and dispensed into 50 200 ml paper containers, which were then sealed with aluminum lids to produce 10 kg of the bone-strengthening lactic acid bacteria beverage of the present invention. Each 200 ml of the bone-strengthening lactic acid bacteria beverage of the present invention contained 64 mg of the SBT10010 strain cells.
[0039] (Example 13) (Preparation of soft drinks for strengthening bones) 3 g of the SBT2054 strain of Example Product 1, 0.75 kg of 50% lactic acid, 5.7 kg of erythritol, 1 kg of flavoring, and 42.547 kg of deionized water were mixed and heated to 40°C, and then stirred and mixed for 10 minutes at 6,000 rpm in a TK homogenizer (TK ROBO MICS; manufactured by Tokushu Kika Kogyo Co., Ltd.). This solution was sterilized at 90°C for 10 minutes and then cooled to 10°C or less to produce 50 kg of the bone strengthening soft drink of the present invention. Note that 200 ml of the bone strengthening soft drink of the present invention contained 12 mg of the SBT2054 strain.
[0040] Example 14 (Preparation of bone strengthening cheese) 9.5 kg of Gouda cheese, 9.5 kg of Cheddar cheese, 4 g of the SBT10561 strain cells of Example Product 1, 200 g of sodium citrate, and 796 g of deionized water were mixed and emulsified at 85° C. After emulsification, the cheese was filled into a carton and cooled at 5° C. for two days and nights to produce 20 kg of the bone-strengthening cheese of the present invention. Note that 100 g of the bone-strengthening cheese of the present invention contained 20 mg of the SBT10561 strain cells.
[0041] Example 15 (Preparation of margarine for strengthening bones) 2 kg of hardened soybean oil, 4 kg of refined soybean oil, 2.5 kg of palm oil, and 50 g of glycerin fatty acid ester were mixed to prepare an oil layer. Next, 20 g of the SBT11380 strain cells of Example Product 1, 10 g of lactic acid, and 1420 g of deionized water were mixed and added to the oil layer to obtain a water-in-oil emulsion. This emulsion was cooled, solidified, and stretched in a margarine manufacturing machine to produce 10 kg of bone-strengthening margarine of the present invention. Note that 10 g of the bone-strengthening margarine of the present invention contained 20 mg of the SBT11380 strain cells.
[0042] (Example 16) (Preparation of bone strengthening cream) 4.5 kg of hardened rapeseed oil, 40 g of lecithin, 10 g of monoglycerin fatty acid ester, and 10 g of sorbitan fatty acid ester were mixed to prepare an oil phase. Next, 40 g of the SBT2115 strain of Example Product 1, 400 g of skimmed milk powder, 10 g of sodium caseinate, 20 g of sugar ester, 10 g of phosphate, 5 g of xanthan gum, and 4.955 kg of deionized water were mixed to prepare an aqueous phase. The aqueous phase was heated to 65°C, and the oil phase heated to 70°C was added little by little while stirring, and stirred and mixed at 6,000 rpm for 10 minutes in a TK homomixer (TK ROBO MICS; manufactured by Tokushu Kika Kogyo Co., Ltd.). This was homogenized in a homogenizer to produce 10 kg of bone strengthening cream of the present invention. In addition, 10 g of the bone strengthening cream of the present invention contained 40 mg of the SBT2115 strain.
[0043] (Example 17) (Preparation of bone strengthening pudding) 2000g of honey, 4g of the SBT1848 strain of Example Product 1, 800g of skim milk powder, 300g of mascarpone, 700g of liquid water, 500g of granulated sugar, 250g of fresh cream, 200g of butter, 400g of sweetened egg yolk, 40g of gelatin, 15g of agar, 120g of locust bean gum, and 4671g of deionized water were mixed to obtain a pudding mix. This pudding mix was stirred and mixed at 6,000 rpm for 10 minutes in a TK homomixer (TK ROBO MICS; manufactured by Tokushu Kika Kogyo Co., Ltd.), heated to 60°C to dissolve, and then filled into containers at 100g each and cooled to produce 100 bone-strengthening puddings of the present invention. Note that 100g of the bone-strengthening pudding of the present invention contained 40mg of the SBT1848 strain.
[0044] (Example 18) (Preparation of bone strengthening jelly) 4.4 g of the SBT2483 strain of Example Product 2, 2000 g of fructose, 1500 g of granulated sugar, 500 g of water, 100 g of agar, 10 g of flavoring, and 5885.6 g of deionized water were mixed, stirred and mixed at 6,000 rpm for 10 minutes in a TK homogenizer (TK ROBO MICS; manufactured by Tokushu Kika Kogyo Co., Ltd.), heated to 50°C for dissolution, and then packed in containers at 100 g each and cooled to produce 100 bone-strengthening jellies of the present invention. Each 100 g of bone-strengthening jelly of the present invention contained 44 mg of the SBT2483 strain.
[0045] (Example 19) (Preparation of bone strengthening wafers) 9.2 g of the SBT10535 strain of Example 3, 8.5 kg of wheat flour, 1.21 kg of cornstarch, 0.22 kg of palm oil, and 0.05 kg of leavening agent were mixed, and then an appropriate amount of deionized water was added to prepare a batter, which was then baked in a wafer baking machine to produce 10 kg of bone-strengthening wafers of the present invention. Note that 50 g of the bone-strengthening wafers of the present invention contained 46 mg of the SBT10535 strain of bacteria. [Industrial Applicability]
[0046] According to the present invention, it is possible to provide a bone strengthening composition which can be taken for a long period of time, is highly safe, has an effect of promoting the proliferation of osteoblasts, and has a remarkable bone strengthening effect through an effect of inhibiting the differentiation of osteoclasts and bone resorption by said cells. Therefore, by taking the composition of the present invention, it is possible to prevent or treat various bone diseases such as osteoporosis, bone fractures, rheumatism, and arthritis. [Accession number]
[0047] [Reference to deposited biological material] (1) Lactobacillus delbrueckii subsp. bulgaricus SBT0056 strain (a) The name and address of the depository institution that deposited the biological material National Institute of Technology and Evaluation, Patent Microorganism Depository Center Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (Postal Code 292-0818) Date of deposit of biological material in a depository institution in the Republic of Korea November 25, 2019 The accession number given to the deposit by the depository institution in question NITE P-03073 (2) Lactobacillus delbrueckii subsp. bulgaricus SBT2115 strain (a) The name and address of the depository institution that deposited the biological material National Institute of Technology and Evaluation, Patent Microorganism Depository Center Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (Postal Code 292-0818) Date of deposit of biological material in a depository institution in the Republic of Korea November 25, 2019 The accession number given to the deposit by the depository institution in question NITE P-03074 (3) Lactobacillus helveticus SBT2161 strain (a) The name and address of the depository institution that deposited the biological material National Institute of Technology and Evaluation, Patent Microorganism Depository Center Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (Postal Code 292-0818) Date of deposit of biological material in a depository institution in the Republic of Korea September 18, 2013 (original deposit date) The accession number given to the deposit by the depository institution in question NITE BP-01707 (4) Lactobacillus helveticus SBT11380 strain (a) The name and address of the depository institution that deposited the biological material National Institute of Technology and Evaluation, Patent Microorganism Depository Center Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (Postal Code 292-0818) Date of deposit of biological material in a depository institution in the Republic of Korea February 21, 2018 (original deposit date) May 27, 2019 (the date of transfer from the original deposit to the deposit under the Budapest Treaty) The accession number given to the deposit by the depository institution in question NITE BP-02644 (5) Lactobacillus helveticus strain 2192A (a) The name and address of the depository institution that deposited the biological material National Institute of Technology and Evaluation, Patent Microorganism Depository Center Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (Postal Code 292-0818) Date of deposit of biological material in a depository institution in the Republic of Korea November 25, 2019 The accession number given to the deposit by the depository institution in question NITE P-03077 (6) Lactobacillus gasseri SBT2054 strain (a) The name and address of the depository institution that deposited the biological material National Institute of Technology and Evaluation, Patent Microorganism Depository Center Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (Postal Code 292-0818) Date of deposit of biological material in a depository institution in the Republic of Korea November 25, 2019 The accession number given to the deposit by the depository institution in question NITE P-03076 (7) Lactobacillus gasseri SBT1848 strain (a) The name and address of the depository institution that deposited the biological material National Institute of Technology and Evaluation, Patent Microorganism Depository Center Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (Postal Code 292-0818) Date of deposit of biological material in a depository institution in the Republic of Korea November 25, 2019 The accession number given to the deposit by the depository institution in question NITE P-03075 (8) Lactobacillus reuteri SBT10010 strain (a) The name and address of the depository institution that deposited the biological material National Institute of Technology and Evaluation, Patent Microorganism Depository Center Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (Postal Code 292-0818) Date of deposit of biological material in a depository institution in the Republic of Korea June 26, 2019 (original deposit date) July 13, 2020 (the date of transfer from the original deposit to the deposit under the Budapest Treaty) The accession number given to the deposit by the depository institution in question NITE BP-02997 (9) Lactococcus lactis subsp. lactis SBT0625 strain (a) The name and address of the depository institution that deposited the biological material National Institute of Technology and Evaluation, Patent Microorganism Depository Center Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (Postal Code 292-0818) Date of deposit of biological material in a depository institution in the Republic of Korea November 25, 2019 (After the date of the original deposit, we applied for a transfer to a deposit under the Budapest Treaty based on the original deposit, and after the completion of the viability confirmation test, we received a letter notifying us of the receipt and accession number. The receipt and accession number is ABP-03078.) The accession number given to the deposit by the depository institution in question NITE P-03078 (10) Lactococcus lactis subsp. lactis SBT2483 strain (a) The name and address of the depository institution that deposited the biological material National Institute of Technology and Evaluation, Patent Microorganism Depository Center Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (Postal Code 292-0818) Date of deposit of biological material in a depository institution in the Republic of Korea November 25, 2019 The accession number given to the deposit by the depository institution in question NITE P-03081 (11) Lactococcus lactis subsp. lactis SBT1223 (a) The name and address of the depository institution that deposited the biological material National Institute of Technology and Evaluation, Patent Microorganism Depository Center Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (Postal Code 292-0818) Date of deposit of biological material in a depository institution in the Republic of Korea July 8, 2019 The accession number given to the deposit by the depository institution in question NITE P-03003 (12) Lactococcus lactis subsp. lactis SBT1554 strain (a) The name and address of the depository institution that deposited the biological material National Institute of Technology and Evaluation, Patent Microorganism Depository Center Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (Postal Code 292-0818) Date of deposit of biological material in a depository institution in the Republic of Korea November 25, 2019 The accession number given to the deposit by the depository institution in question NITE P-03079 (13) Lactococcus lactis subsp. lactis SBT2397 (a) The name and address of the depository institution that deposited the biological material National Institute of Technology and Evaluation, Patent Microorganism Depository Center Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (Postal Code 292-0818) Date of deposit of biological material in a depository institution in the Republic of Korea November 25, 2019 The accession number given to the deposit by the depository institution in question NITE P-03080 (14) Bifidobacterium breve SBT10535 strain (a) The name and address of the depository institution that deposited the biological material National Institute of Technology and Evaluation, Patent Microorganism Depository Center Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (Postal Code 292-0818) Date of deposit of biological material in a depository institution in the Republic of Korea November 25, 2019 The accession number given to the deposit by the depository institution in question NITE P-03071 (15) Bifidobacterium breve SBT10561 strain (a) The name and address of the depository institution that deposited the biological material National Institute of Technology and Evaluation, Patent Microorganism Depository Center Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (Postal Code 292-0818) Date of deposit of biological material in a depository institution in the Republic of Korea November 25, 2019 (After the date of the original deposit, we applied for a transfer to a deposit under the Budapest Treaty based on the original deposit, and after the completion of the viability confirmation test, we received a letter notifying us of the receipt and accession number. The receipt and accession number is ABP-03072.) The accession number given to the deposit by the depository institution in question NITE P-03072 (16) Bifidobacterium adolescentis SBT10549 strain (a) The name and address of the depository institution that deposited the biological material National Institute of Technology and Evaluation, Patent Microorganism Depository Center Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (Postal Code 292-0818) Date of deposit of biological material in a depository institution in the Republic of Korea November 25, 2019 The accession number given to the deposit by the depository institution in question NITE P-03070
Claims
1. A composition for promoting osteoblast proliferation, comprising as an active ingredient a bacterial cell and / or a culture of a bacterium belonging to the genus Lactobacillus or Bifidobacterium, wherein the bacterium belonging to the genus Lactobacillus or Bifidobacterium is one or more selected from the group consisting of Lactobacillus delbrueckii, Lactobacillus gasseri, and Bifidobacterium breve.
2. The composition according to claim 1, wherein the bacterium belonging to Lactobacillus delbrueckii is a bacterium belonging to Lactobacillus delbrueckii subsp. bulgaricus.
3. A composition for promoting osteoblast proliferation, comprising as an active ingredient a bacterial cell and / or a culture product thereof of a bacterium belonging to the genus Lactobacillus, Lactococcus, or Bifidobacterium, wherein the bacterium belonging to the genus Lactobacillus, Lactococcus, or Bifidobacterium is selected from the group consisting of Lactobacillus delbrueckii subsp. bulgaricus SBT2115 strain (NITE P-03074), SBT0056 strain (NITE P-03073), Lactobacillus gasseri ... gasseri SBT2115 strain (NITE P-03074), SBT0056 strain (NITE P-03073), Lactobacillus gasseri SBT2115 strain (NITE P-03074), SBT0056 strain (NITE P-03073), Lactobacillus gasseri SBT2115 strain (NITE P-03074), SBT gasseri) SBT2054 strain (NITE P-03076), SBT1848 strain (NITE BP-03075), Lactobacillus reuteri) SBT10010 strain (NITE BP-02997), Lactococcus lactis subsp. lactis) SBT0625 strain (NITE BP-03078), SBT2483 strain (NITE P-03081), SBT1223 strain (NITE P-03003), SBT1554 strain (NITE P The composition is characterized in that it is one or more selected from the group consisting of Bifidobacterium breve SBT10535 strain (NITE P-03071), SBT10561 strain (NITE BP-03072), and Bifidobacterium breve SBT10535 strain (NITE P-03079).
4. A food or drink, a nutritional composition, a feed or a pharmaceutical for promoting osteoblast proliferation, comprising the composition for promoting osteoblast proliferation according to any one of claims 1 to 3.
5. A novel lactic acid bacterium, Lactobacillus delbrueckii subsp. bulgaricus SBT0056 strain (NITE P-03073).
6. Novel lactic acid bacterium, Lactococcus lactis subsp. lactis SBT0625 strain (NITE BP-03078).
7. A novel lactic acid bacterium, Lactococcus lactis subsp. lactis SBT2483 strain (NITE P-03081).
8. A novel lactic acid bacterium, Lactococcus lactis subsp. lactis SBT1223 strain (NITE P-03003).
9. Novel lactic acid bacterium, Lactococcus lactis subsp. lactis SBT1554 strain (NITE P-03079).
10. A novel lactic acid bacterium, Lactococcus lactis subsp. lactis SBT2397 strain (NITE P-03080).
11. A novel bifidobacterium, Bifidobacterium breve SBT10535 strain (NITE P-03071).
12. A novel bifidobacterium, Bifidobacterium breve strain SBT10561 (NITE BP-03072).
Citation Information
Patent Citations
Mineral absorption accelerating agent
JP1997194384A
Bone resorption inhibitor
JP2004315477A
Lactic bacterium having aging-inhibiting activity and application thereof
JP2006256993A
Selection and use of lactic acid bacteria to prevent bone loss in mammals
JP2015526389A
Food materials useful for the prevention and improvement of metabolic bone diseases, and therapeutic agents for metabolic bone diseases comprising the active ingredients of said materials.
JP4750991B2
